BPG is committed to discovery and dissemination of knowledge
Articles in Press
2/5/2026 7:37:28 AM | Browse: 1 | Download: 0
| Category |
Radiology, Nuclear Medicine & Medical Imaging |
| Manuscript Type |
Retrospective Study |
| Article Title |
Tumor-related imaging parameters predict response and survival after neoadjuvant chemoradiotherapy in rectal cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ting-ting Nie, Yu-Xia Li, Xuan Yang, Tao Liu, Xiao-Hui Niu, Xiao-Fang Guo and Yu-Lin Liu |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Guiding Program of Natural Science Foundation of Hubei Province |
No. 2024AFC050 |
| Special Project of Biomedical Research Center of Hubei Cancer Hospital |
No. 2022SWZX06 |
| Hubei Province “Chutian Talents Program” Medical and Health Personnel Project |
No. CTYC001 |
|
| Corresponding Author |
Xiao-Fang Guo, MD, PhD, Department of Radiology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 116 Zhuodaoquan South Road, Hongshan District, Wuhan 430079, Hubei Province, China. guoxiaofang2001@163.com |
| Key Words |
Sarcopenia; Rectal cancer; Neoadjuvant therapy; Response; Overall survival |
| Core Tip |
This study evaluated the impact of pretreatment sarcopenia and tumor-related magnetic resonance imaging parameters on the response to neoadjuvant chemoradiotherapy and overall survival in rectal cancer patients. The results show that while sarcopenia was not an independent predictor of treatment response or survival, tumor-related factors such as tumor length, mesorectal fascia involvement, and clinical T/N stage were significant predictors. These findings highlight the value of tumor-related imaging parameters in pretreatment risk stratification and personalized management for rectal cancer patients undergoing neoadjuvant chemoradiotherapy. |
| Citation |
Nie TT, Li YX, Yang X, Liu T, Niu XH, Guo XF, Liu YL. Tumor-related imaging parameters predict response and survival after neoadjuvant chemoradiotherapy in rectal cancer. World J Gastrointest Oncol 2026; In press |
 |
Received |
|
2025-12-15 03:59 |
 |
Peer-Review Started |
|
2025-12-15 03:59 |
 |
First Decision by Editorial Office Director |
|
2025-12-24 09:40 |
 |
Return for Revision |
|
2025-12-24 09:40 |
 |
Revised |
|
2026-01-06 01:57 |
 |
Publication Fee Transferred |
|
2026-01-08 12:11 |
 |
Second Decision by Editor |
|
2026-02-05 02:47 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2026-02-05 07:37 |
 |
Articles in Press |
|
2026-02-05 07:37 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
|
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345